Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • Big pharma
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
    • Big pharma
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
Healthcare inequity

How we drive change

We mobilise healthcare companies to solve chronic issues of availability and affordability, so that more people in low- and middle-income countries can access vital healthcare products. Using our proven model for change, we work with stakeholders to identify what needs to be done and help drive solutions.

Our proven model for catalysing change

As an independent research foundation, we catalyse change by triggering essential healthcare companies to play their part and raise their game on access. To do so, we use a combination of data, research insights, rankings and report cards, including our influential Access to Medicine Index. In addition, we leverage a network of influential stakeholders, including investors, governments, and the public.

Our tried-and-tested model for change has three key components:

  • Building consensus on where companies can and should act to improve access to medicine
    Every two years, we translate the stakeholder consensus into clear metrics for measuring company behaviour, which we publish in our methodology reports. 

  • Benchmarking companies and stimulating competition by identifying top performers
    When companies’ positive actions are publicly recognised, this triggers other companies to join a “race to do well” on priority health targets and topics.

  • Advocating best practices identified through our research
    We engage actively with all stakeholders to facilitate the wider application of best practices and the development of new approaches to long-standing access challenges.

Jayasree K. Iyer, CEO of the Foundation, talking at the expert panel discussion on ‘Future-proofing Health Systems’ at the World Economic Forum - May 2022

Jayasree K. Iyer, CEO of the Foundation, talking at the expert panel discussion on ‘Future-proofing Health Systems’ at the World Economic Forum - May 2022

Marijn Verhoef, Director of Operations and Research, speaking on the panel ‘Addressing Environmental Aspects of AMR’ at the World AMR Congress in Washington – September 2022

Marijn Verhoef, Director of Operations and Research, speaking on the panel ‘Addressing Environmental Aspects of AMR’ at the World AMR Congress in Washington – September 2022

Jayasree K. Iyer, CEO of the Foundation, speaking at CEPI’s Global Pandemic Preparedness Summit as a part of a panel discussion on the topic ‘The Urgency of Now: Planning for the Next Disease X’ – March 2022

Jayasree K. Iyer, CEO of the Foundation, speaking at CEPI’s Global Pandemic Preparedness Summit as a part of a panel discussion on the topic ‘The Urgency of Now: Planning for the Next Disease X’ – March 2022

Fatema Rafiqi, Research Programme Manager, talking at the expert panel discussion on AMR organized in collaboration with Global Antibiotic R&D Partnership (GARDP) – June 2022

Fatema Rafiqi, Research Programme Manager, talking at the expert panel discussion on AMR organized in collaboration with Global Antibiotic R&D Partnership (GARDP) – June 2022

Jayasree K. Iyer, CEO of the Foundation, with Bill Gates and others in a LIVE World Economic Forum expert panel, discussing how new leadership, policy and business models are rewriting the global health playbook – January 2018

Jayasree K. Iyer, CEO of the Foundation, with Bill Gates and others in a LIVE World Economic Forum expert panel, discussing how new leadership, policy and business models are rewriting the global health playbook – January 2018

We engage directly with key stakeholders

By working alongside stakeholders on systemic access challenges, we can signal where gaps exist and drive the uptake of best practices. The Access to Medicine Foundation’s teams engage directly with pharmaceutical companies, with governments, policy-makers, donors and NGOs and with the investor community.

  • Large pharmaceutical companies, with their vast resources, portfolios and global reach, have a critical role to play in improving access to medicine. Our company engagement team spurs positive action through direct engagement with pharma companies, in the form of meetings, briefings and workshops. This includes sharing the Foundation’s research results and exploring opportunities and best practices with companies’ leadership and access teams.

Read more about how we engage with pharmaceutical companies
  • Governments and policy-makers have the power to set enabling conditions to facilitate access. Our government engagement team liaises with governments, private foundations, multilateral organisations and non-governmental organisations working to improve global health and access to medicine. By sharing our research findings, we help policy-makers identify key opportunities for collaboration and change-making. 

Read more about our work with government and policy-makers
  • Investors have an influential role regarding the direction of investee companies. Our team helps institutional investors to use the Foundation’s findings and analysis to better manage risks and opportunities for pharmaceutical companies. To date, over 150 investors managing assets of more than USD 25 trillion have committed to use our data and insights. 

Read more about our work with investors

Our work has a wide impact

Our work has already made a significant contribution to advancing the pharmaceutical industry’s engagement with access issues. Independent third-party evaluation has confirmed the validity of our three-part model for change and the effectiveness of the mechanisms we use to mobilise the healthcare industry to improve access.

Our Access to Medicine Index is the most comprehensive, long-running survey of company behaviour regarding access to medicine, and the primary benchmark of its kind. As a tool for learning and discussion, the Index helps companies understand the scope of their own activities and how to implement best practices, while stimulating healthy competition between firms to do better.

We are committed to making all our findings freely and publicly available. By openly publishing our data on company behaviour, we contribute to greater transparency in the pharmaceutical industry, empowering change from within. Meanwhile, armed with our insights, policy-makers and investors are able to make better-informed decisions about how to engage with healthcare companies for the greater good.

Achievements so far

Read more about the impact of our work

Read more

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved